Safety Considerations for New Therapies
Experts discusses concerns related to the use of new agents, focusing on intraocular inflammation (IOI) and potential batch variations in biologics faricimab and aflibercept. He emphasizes close monitoring for IOI and advises clinicians to scrutinize patients for any signs of inflammation during follow-up visits.
EP: 1.Navigating Step Therapy in nAMD and DME
EP: 2.Role of Biosimilars in nAMD and DME Step Therapy
EP: 3.Overview of the Newest Therapies for AMD and DME: Faricimab and Aflibercept 8mg
EP: 4.Aligning Clinical Trial Retreatment Criteria to Clinical Practice
EP: 5.Perspectives on Retinal Fluid Management in nAMD and DME
EP: 6.Perspectives on Loading Dose and Treatment Extension With New Therapies
EP: 7.Using Steroids in DME Treatment
EP: 8.Patient Selection for New nAMD and DME Therapies
EP: 9.Early Real-World Experiences With Faricimab and Aflibercept 8mg
EP: 10.Safety Considerations for New Therapies
EP: 11.Promoting Treatment Adherence in nAMD and DME
Summary
Concerns arise with the use of new agents for neovascular AMD and DME, particularly regarding intraocular inflammation (IOI) and batch-to-batch variations inherent in biologics. The clinicians recommend closely monitoring patients for signs of IOI, vitreous cell presence, and other adverse events, especially with high-dose formulations like faricimab and aflibercept 8mg. FDA-mandated labeling changes acknowledging IOI risk reinforce safety measures, although overall risk-benefit ratios remain favorable. The transition from vials to prefilled syringes with higher volumes prompts consideration of potential complications such as increased intraocular pressure, particularly in patients with glaucoma. Techniques like ocular massage and vigilant monitoring help mitigate risks associated with higher volume injections, ensuring optimal safety for patients receiving these newer agents.
This summary was AI-generated and edited for clarity.
